Mechanical ventilation

Global Continuous Positive Airway Pressure Market (2020 to 2026) - Featuring Airon, Apex Medical and Asahi Kasei Among Others

Retrieved on: 
Tuesday, April 13, 2021
Medicine, Clinical medicine, Mechanical ventilation, Medical specialties, Medical equipment, Continuous positive airway pressure, Positive airway pressure, Fisher & Paykel Healthcare, ResMed, Apex Medical

b'DUBLIN, April 13, 2021 /PRNewswire/ -- The "Global Continuous Positive Airway Pressure (CPAP) Market: Analysis and Forecast, 2020-2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe purpose of the study is to enable the reader to gain a holistic view of the global CPAP market by each of the aforementioned segments.\nThe report constitutes an in-depth analysis of the global CPAP market, including a thorough analysis of the different end-users.

Key Points: 
  • b'DUBLIN, April 13, 2021 /PRNewswire/ -- The "Global Continuous Positive Airway Pressure (CPAP) Market: Analysis and Forecast, 2020-2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe purpose of the study is to enable the reader to gain a holistic view of the global CPAP market by each of the aforementioned segments.\nThe report constitutes an in-depth analysis of the global CPAP market, including a thorough analysis of the different end-users.
  • The study also provides exhaustive information on disease epidemiology, competitive landscape, brand share landscape, market share of the leading players, number of CPAP units shipped, as well as other vital information with respect to the global CPAP market.
  • The report considers CPAP device and Ventilators (offering CPAP mode) manufacturers.\nEnd User (Hospitals and Clinics, Nursing Homes, Elderly Care Centers, and Home-Use)\nAiron Corporation, APEX MEDICAL CORP., Asahi Kasei Corporation, BMC Medical Co., Ltd, Dragerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited, General Electric Company, Getinge AB, Koninklijke Philips N.V., Lowenstein Medical GmbH & Co. KG, Medical Depot, Inc. dba drives DeVilbiss Healthcare LLC, Medtronic Plc, ResMed, Inc., Smiths Group plc (Smiths Medical) and VYAIRE MEDICAL, INC.\nKey Questions Answered in this Report:\nHow has COVID-19 impacted the adoption of CPAP devices in the market?\nWhat are the key regulations which influence the adoption of CPAP devices in the market?\nWhat are some of the key brands in the global and regional CPAP market?\nWho are the top competitors in each region?\nWhat are some of the key factors influencing the growth in adopting CPAP devices across the globe?\nHow do the brands compare against each other in terms of unit shipments?\nWhat are the fastest-growing countries in terms of CPAP adoption?\nWhich are the key diseases driving the adoption of CPAP devices across the world?\nWhat are the key strategies being adopted by market players in the global CPAP market?\nWho are the most common end-users of CPAP devices, and how are the end-use segment expected to grow in the future?\nFollowing are some of the key contents of the report:\nThis section includes exhaustive information on the epidemiology of key disease indications for the CPAP domain.\nThis section encompasses a description of the current patent landscape in the continuous positive airway pressure field.\nThis section comprises the information on the regulatory framework for various regulatory bodies associated with granting approval to CPAP devices.\nThis section of the report encompasses the following:\n'

Insights on the Continuous Positive Airway Pressure Global Market to 2026 - Rising Number of Startups Driving Innovation - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 8, 2021
Medical devices, Health, Medicine, Clinical medicine, Mechanical ventilation, Medical specialties, Continuous positive airway pressure, Positive airway pressure, Bubble CPAP

The "Global Continuous Positive Airway Pressure (CPAP) Market: Analysis and Forecast, 2020-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Continuous Positive Airway Pressure (CPAP) Market: Analysis and Forecast, 2020-2026" report has been added to ResearchAndMarkets.com's offering.
  • The purpose of the study is to enable the reader to gain a holistic view of the global CPAP market by each of the aforementioned segments.
  • The report constitutes an in-depth analysis of the global CPAP market, including a thorough analysis of the different end-users.
  • What are the key strategies being adopted by market players in the global CPAP market?

The CPAP Shop and Sleep Care online Partner to Offer Comprehensive Sleep Care Solutions

Retrieved on: 
Wednesday, March 31, 2021
Medicine, Clinical medicine, Medical equipment, Mechanical ventilation, Health sciences, Continuous positive airway pressure, Sleep disorders, Oxygen concentrator, Positive airway pressure

NEW YORK, March 31, 2021 /PRNewswire-PRWeb/ -- The CPAP Shop , an e-commerce retailer of sleep aid equipment, has partnered with Sleep Care online , a national sleep telemedicine services provider, to create a unique, comprehensive sleep care solution.

Key Points: 
  • NEW YORK, March 31, 2021 /PRNewswire-PRWeb/ -- The CPAP Shop , an e-commerce retailer of sleep aid equipment, has partnered with Sleep Care online , a national sleep telemedicine services provider, to create a unique, comprehensive sleep care solution.
  • Patients now have access to cutting-edge technology to diagnose sleep disorders, have one-on-one virtual consultations with board-certified sleep physicians, and receive prescriptions for sleep therapy through Sleep Care online.
  • Sleep experts at The CPAP Shop will then offer customized recommendations for sleep equipment at discounted rates and assist with placing an order and expediting shipping.
  • The Agile Medical family of brands includes The CPAP Shop, The Oxygen Concentrator Supplies Shop, and Sleep Care online.

Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation

Retrieved on: 
Thursday, March 18, 2021
Biotechnology, Pharmaceutical, General Health, Health, Medical devices, Infectious diseases, Hospitals, Clinical trials, Medical specialties, Health, Medicine, Intensive care medicine, COVID-19 drug development, Nucleotides, Remdesivir, Acute respiratory distress syndrome, Coronavirus disease, Mechanical ventilation, Treatment and management of COVID-19, Baricitinib, DEVENT (NCT04377620), the Ruxolitinib Expanded Access Program (EAP) in COVID-19, Jakafi® (ruxolitinib), Incyte

More than half of study patients (55%) received remdesivir and 90% of study patients received corticosteroids prior to or during the study.

Key Points: 
  • More than half of study patients (55%) received remdesivir and 90% of study patients received corticosteroids prior to or during the study.
  • The safety profile was generally consistent with hospitalized patients with COVID-19 and consistent with treatment with ruxolitinib.
  • We look forward to discussing the results of the DEVENT study with regulatory authorities in the United States.
  • The protocol will allow eligible patients with severe COVID-19 associated ARDS with disease severity requiring mechanical ventilation to receive ruxolitinib.

Stimdia Medical Receives FDA Breakthrough Device Designation for the pdSTIM™ System Designed to Facilitate Weaning Patients from Mechanical Ventilation

Retrieved on: 
Thursday, March 18, 2021
FDA, Health, Medical devices, Medical specialties, Respiratory therapy, Medicine, Health care, Ventilator, Mechanical ventilation, Food and Drug Administration, FDA, Health, Medical devices, Medical specialties, Respiratory therapy, Medicine, Health care, Ventilator, Mechanical ventilation, Food and Drug Administration

Stimdia Medical, Inc., an emerging leader in the development of technology to reduce weaning time for patients on mechanical ventilation, today announced the companys pdSTIM System has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).

Key Points: 
  • Stimdia Medical, Inc., an emerging leader in the development of technology to reduce weaning time for patients on mechanical ventilation, today announced the companys pdSTIM System has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
  • Mechanical ventilation is an essential intervention and is utilized in the management of over 10 million patients throughout the world each year.
  • Receiving FDA Breakthrough Device designation for the pdSTIM System will help prioritize the process for obtaining regulatory authorization in the U.S., said Tim Miller, General Manager, Stimdia Medical.
  • We believe the pdSTIM System will help to reduce both length of stay and costs by enabling more rapid weaning of patients from mechanical ventilators.

ALung Announces a Key Milestone Achievement in its VENT-AVOID Pivotal Trial

Retrieved on: 
Tuesday, March 16, 2021
Nursing, Medical Supplies, Finance, Surgery, Health, Medical devices, Hospitals, Professional services, Medical specialties, Clinical medicine, Health, Intensive care medicine, Chronic lower respiratory diseases, Respiratory therapy, Chronic obstructive pulmonary disease, Extracorporeal carbon dioxide removal, Mechanical ventilation, Respiratory disease

ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the recent achievement of a significant milestone - enrollment of 100 patients in its U.S. based VENT-AVOID pivotal trial.

Key Points: 
  • ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the recent achievement of a significant milestone - enrollment of 100 patients in its U.S. based VENT-AVOID pivotal trial.
  • VENT-AVOID is a randomized, controlled pivotal trial (RCT) studying the avoidance or minimization of mechanical ventilation for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AE-COPD).
  • The VENT-AVOID pivotal trial is currently the worlds largest trial ever conducted on the utilization of ECCO2R in AE-COPD with 100 patients now enrolled.
  • Subsequent to receiving Emergency Use Authorization (EUA) from the FDA, ALung has provided ECCO2R therapy to 93 COVID-19 patients worldwide.

ReddyPort™ launches Microphone and Controller--a first-of-its-kind non-invasive ventilation medical technology allowing patient communication

Retrieved on: 
Tuesday, March 16, 2021
Medical specialties, Clinical medicine, Medicine, Mechanical ventilation, Respiratory therapy, Intensive care medicine, Non-invasive ventilation, Niv

For clinicians and family members, it helps ease the frustration of not being able to understand the patient behind the mask, especially during a life-threatening illness.

Key Points: 
  • For clinicians and family members, it helps ease the frustration of not being able to understand the patient behind the mask, especially during a life-threatening illness.
  • "Non-invasive ventilation is often a life-saving patient intervention for respiratory distress, but these ventilation masks create barriers for adequate communication between doctors and patients," said Dr. Quinn M. Snyder, emergency physician in Mesa, Arizona.
  • With the ReddyPort microphone technology, I am no longer deprived of information I need to care for these critical patients."
  • ReddyPort products promote non-invasive ventilation (NIV) success and better care experiences for patients on NIV, providing solutions to help improve satisfaction, reduce risk and cost, enable better workflows, and enhance quality of care.

Quantum Leap Healthcare Collaborative Concludes Apremilast Not Likely to Reduce Time to Recovery or Mortality in Critically Ill Patients in I-SPY COVID Trial

Retrieved on: 
Friday, March 12, 2021
Medical specialties, Health, Phthalimides, Acetamides, Amgen, Apremilast, Intensive care medicine, Coronavirus disease, Mechanical ventilation

SAN FRANCISCO, March 12, 2021 /PRNewswire/ --Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, announced that apremilast (Otezla), made by Amgen, has been dropped for futility.

Key Points: 
  • SAN FRANCISCO, March 12, 2021 /PRNewswire/ --Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, announced that apremilast (Otezla), made by Amgen, has been dropped for futility.
  • The I-SPY COVID Trial is a phase II, open label, adaptive platform trial being conducted in critically ill COVID-19 patients who are receiving high flow oxygen or mechanical ventilation.
  • Patients assigned to the apremilast arm received backbone therapy in combination with 30 mg twice daily of apremilast for up to 14 days.
  • Under the terms of the collaboration agreement, Quantum Leap Healthcare Collaborative is the trial sponsor and manages all study operations.

Ventec Life Systems Appoints Jim Alwan as President and Chief Executive Officer

Retrieved on: 
Monday, March 8, 2021
Nursing, Health, Medical devices, Hospitals, Other Health, General Health, Biotechnology, Mechanical ventilation, Ventec Life Systems, Alwan

Ventec Life Systems today announced that its Board of Directors has appointed Jim Alwan as President and Chief Executive Officer, effective March 15, 2021.

Key Points: 
  • Ventec Life Systems today announced that its Board of Directors has appointed Jim Alwan as President and Chief Executive Officer, effective March 15, 2021.
  • Alwan brings to Ventec Life Systems extensive medical device leadership experience with more than 25 years developing and managing healthcare products.
  • Jim brings a track record of industry accomplishment and effective leadership to Ventec, said Ventec Life Systems Board of Directors Chairman Jim Hickey.
  • I am delighted to join Ventec Life Systems to expand upon the unprecedented growth and remarkable progress of this team, said Alwan.

Masimo Announces U.S. Release of softFlow® High-Flow Nasal Cannula Therapy

Retrieved on: 
Tuesday, February 23, 2021
Biotechnology, Health, FDA, Medical devices, Infectious diseases, Hospitals, Clinical trials, Other Health, Medicine, Clinical medicine, Medical specialties, Respiratory therapy, Medical equipment, Infectious diseases, Masimo, Intensive care medicine, Nasal cannula, Mechanical ventilation, Oxygen therapy, Ventilator

Masimo (NASDAQ: MASI) today announced the U.S. introduction of softFlow, innovative pulmonary care therapy which provides nasal high-flow warmed and humidified respiratory gases to spontaneously breathing patients.

Key Points: 
  • Masimo (NASDAQ: MASI) today announced the U.S. introduction of softFlow, innovative pulmonary care therapy which provides nasal high-flow warmed and humidified respiratory gases to spontaneously breathing patients.
  • The technology, available on the softFlow 50, offers adult patients high-flow respiratory support through a soft nasal cannula by generating a consistent high flow of warm, humidified air or air/oxygen mixture.
  • We realize that high-flow nasal therapy could potentially help avoid invasive mechanical ventilation and its associated risks of ventilator-induced lung injury and hospital-acquired pneumonia.
  • Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation platform, and include Iris Gateway, Patient SafetyNet, Replica, Halo ION, UniView, UniView 60, and Masimo SafetyNet.